Patents by Inventor Masahiro Kamaura

Masahiro Kamaura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190119225
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
  • Patent number: 10214498
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 26, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
  • Publication number: 20180237404
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 23, 2018
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro BANNO, Masahiro KAMAURA, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
  • Patent number: 9975903
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
  • Patent number: 9944596
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 17, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Takahiko Taniguchi, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
  • Publication number: 20170349605
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].
    Type: Application
    Filed: December 24, 2015
    Publication date: December 7, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Minoru SASAKI, Fumiaki KIKUCHI, Zenichi IKEDA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Shigekazu SASAKI, Koichiro FUKUDA, Kazuaki TAKAMI, Yoshihiro BANNO, Masahiro KAMAURA
  • Publication number: 20170233339
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 17, 2017
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro BANNO, Masahiro KAMAURA, Takahiko TANIGUCHI, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
  • Patent number: 9487509
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: November 8, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Tomohiro Kaku, Masahiro Kamaura
  • Publication number: 20140066420
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Application
    Filed: October 16, 2013
    Publication date: March 6, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Tomohiro KAKU, Masahiro KAMAURA
  • Patent number: 8586571
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: November 19, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Tomohiro Kaku, Masahiro Kamaura
  • Patent number: 8410089
    Abstract: A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, A1: CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: —COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: April 2, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kentaro Rikimaru, Hiroshi Imoto, Masahiro Kamaura
  • Patent number: 8383647
    Abstract: The present invention provides a compound having a melanin-concentrating hormone receptor antagonistic action and low toxicity, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: February 26, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshiki Murata, Masahiro Kamaura
  • Patent number: 8338622
    Abstract: The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: December 25, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Masahiro Kamaura, Nobuo Cho
  • Publication number: 20120035213
    Abstract: The present invention provides a compound having a melanin-concentrating hormone receptor antagonistic action and low toxicity, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 9, 2012
    Inventors: Toshiki Murata, Masahiro Kamaura
  • Publication number: 20120028962
    Abstract: A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: —COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.
    Type: Application
    Filed: February 17, 2010
    Publication date: February 2, 2012
    Inventors: Kentaro Rikimaru, Hiroshi Imoto, Masahiro Kamaura
  • Publication number: 20110251187
    Abstract: The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 13, 2011
    Inventors: Shizuo Kasai, Masahiro Kamaura, Nobuo Cho
  • Publication number: 20110015225
    Abstract: The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 31, 2009
    Publication date: January 20, 2011
    Inventors: Toshiki Murata, Kazuaki Takami, Masahiro Kamaura, Tomohiro Okawa
  • Publication number: 20100292206
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Application
    Filed: October 17, 2008
    Publication date: November 18, 2010
    Inventors: Shizuo Kasai, Tomohiro Kaku, Masahiro Kamaura
  • Patent number: 6201123
    Abstract: A catalyst composition for organic a symmetric synthesis is provided, which comprises: (A) a lanthanoid element ion; (B) a binaphthol, and (C) a nitrogen and/or phosphorus compound such as lutidine-N-oxide, 1,3-dimethyl-2-imidazolldinone, hexamethyl-phosphortriamide, triphenylphosphine oxide, tri(2-methylphenyl)phosphine oxide or tri(4-methylphenyl )phosphine oxide. Asymmetric epoxidation of an enone is conducted by allowing an enone to react with an oxidizing agent in the presence of the catalyst composition or a catalyst solution containing the catalyst composition.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: March 13, 2001
    Assignee: Techno Polymer Co., Ltd.
    Inventors: Kazuhiro Daikai, Masahiro Kamaura, Takeshi Hanamoto, Junji Inanaga